Kynamro(mipomersen) from Genzyme/Sanofi and Isis Pharma has been filed at the FDA as a New Drug Application for the rare...
The FDA 0n 29 January 2013 approved Kynamro (mipomersen sodium) injection, from Genzyme/Sanofi, as an addition to lipid-lowering medications and...
Genzyme, a Sanofi company and Isis Pharmaceuticals Inc. have announced that the Committee for Medicinal Products for Human Use (CHMP)...
Isis Pharmaceuticals has announced that the FOCUS FH Phase III study of Kynamro (mipomersen sodium) in patients with severe heterozygous...
Genzyme, a Sanofi company and Isis Pharmaceuticals have announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA...